0M2N.LSE Orion Oyj Series A
- Market cap
- EUR 8.66B
- P/E
- 73.4x
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2021.
Is 0M2N.LSE undervalued?
Graham numberThe Graham number of Orion Oyj Series A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Orion Oyj Series A fundamental analysis
No fundamental analysis for Orion Oyj Series A yet.
Orion Oyj Series A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Orion Oyj Series A
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart fa…
Full company profileOrion Oyj Series A financial statements
Orion Oyj Series A annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.07B | 1.03B | 978M | 1.05B | 1.08B | - |
| Gross Profit | 652M | 616M | 590M | 633M | 651M | - |
| Operating Income | 315M | 284M | 253M | 253M | 280M | - |
| Net Income | 249M | 226M | 330M | 200M | 220M | - |
| Balance Sheet | ||||||
| Total Assets | 1.06B | 1.06B | 1.15B | 1.04B | 1.12B | - |
| Total Liabilities | 422M | 376M | 374M | 256M | 384M | - |
| Shareholders' Equity | 641M | 680M | 773M | 779M | 731M | - |
| Cash & Short-term Investments | 232M | 164M | 284M | 149M | 294M | - |
| Total Debt | 150M | 150M | 600K | 6.70M | 106M | - |
| Cash Flow | ||||||
| Operating Cash Flow | 249M | 228M | 231M | 271M | 299M | 216M |
| Capital Expenditure | 47.7M | 67.1M | 38.1M | 28.7M | 34.0M | 47.0M |
| Ratios | ||||||
| ROE | 38.8% | 33.2% | 42.7% | 25.7% | 30.1% | - |
| ROA | 23.4% | 21.4% | 28.8% | 19.3% | 19.7% | - |
| Net Profit Margin | 23.2% | 21.9% | 33.8% | 19.1% | 20.4% | - |
| Debt to Equity | 0.23x | 0.22x | 0.00x | 0.01x | 0.14x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Orion Oyj Series A dividends
Orion Oyj Series A has not paid dividends in the last 9 fiscal years.
Who owns Orion Oyj Series A
- Insiders 32.89%
- Institutions 8.11%
- Public & others 59.00%
- Shares outstanding 141M
- Free float 123M
Orion Oyj Series A company profile
- Company name
- Orion Oyj Series A
- Ticker
- 0M2N.LSE
- ISIN
- FI0009014369
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 4,215
- Fiscal year end
- December
- Address
- Orionintie 1A, Espo, Finland, 02200
- Phone
- 358 10 4261
- Website
- orionpharma.com
About Orion Oyj Series A
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychotic; Trexan for rheumatoid arthritis and cancer; Easyhaler product portfolio for asthma and COPD; and Dexdor, Precedex, and Dexmedetomidine products for human use. The company also provides Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells drugs and products manufactured by other companies. Additionally, the company provides self-care products, including non-prescription medicines, cosmetics, dietary supplements, vitamins, and skincare products. It also offers its products online. The company has a licensing agreement with Tenax Therapeutics, Inc. to develop oral levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF); and Bayer for the development and commercialisation of darolutamide Nubeqa. Orion Oyj was founded in 1917 and is headquartered in Espo, Finland.
Orion Oyj Series A management
10- Dr. Liisa Hurme Ph.D.President, CEO & Chairman of Executive Management Board · born 1967
- Mr. Rene Lindell M.Sc., Ph.D.CFO & Member of Group Executive Management Board · born 1976
- Ms. Satu Ahomäki M.Sc., M.Sc. (Econ.)Executive VP of Generics and Consumer Health & Member of the Exe. Mgmt. Board · born 1966
- Prof. Outi Vaarala M.D., Ph.D.Executive VP of Research & Development and Member of the Exe. Mgmt. Board · born 1962
- Mr. Juhani Kankaanpaa M.Sc.Executive VP of Global Operations & Member of Executive Management Board · born 1980
- Mr. Niclas Lindstedt EMBA, M.Sc.Executive VP of Animal Health & Member of the Exe. Mgmt. Board · born 1966
- Mr. Hao Pan M.Sc.Executive VP of the Branded Products & Member of the Exe. Mgmt. Board · born 1971
- Ms. Julia Irene MachareyExecutive VP of People & Culture & Member of Management Board · born 1977
- Mr. Mikko KemppainenGeneral Counsel, Secretary to the Board & Member of Executive Management Board · born 1972
- Mr. Berkeley VincentExecutive Vice President of Innovative Medicines & Member of Management Board · born 1977